InvestorsHub Logo
icon url

Robert C Jonson

02/19/10 8:47 PM

#47816 RE: CHEVYGUY #47815

Anyone hear anything about the Duke paper?


Yep!
icon url

geocappy1

02/19/10 11:29 PM

#47817 RE: CHEVYGUY #47815

"In Press"
icon url

cjgaddy

02/20/10 10:14 AM

#47818 RE: CHEVYGUY #47815

CHEVY, these 4 statements (2 direct / 2 indirect) are the latest I’ve heard about the (1st) Duke/Haynes pub. involving pre-clinical work with the Duke/PPHM/Gates/CHAVI HIV Collab. Anti-PS/Anti-Lipid mabs:

5-1-09, Dr. Barton Haynes (CHAVI Update): “The (CHAVI) B Cell Discovery Team has defined a class of anti-lipid antibodies with breadth of protection in vitro PBMC assay for R5 transmitted/founder strains. (Nature Medicine, submitted 2009)”.
http://tinyurl.com/d2ucmw

8-4-09, Editor/NatMedicine (email to ME): “...As a general note, though, I can tell you that a paper submitted in may to any Nature journal is unlikely to appear published within 3 months. Papers often go through multiple rounds of review, and 10-12 months delays are not uncommon...”

1-5-10, by: geocappy1 iHub #46480
Please see following response from Chavi to the following email sent to them yesterday.
In the May 1, 2009 Executive Summary the Paragragh below was stated. Can you tell me if the article is still in process, accepted for publication or withdrawn?
“Completed enrollment in CHAVI 005 protocol of study of protective antibodies in autoimmune diseases and defined a class of anti-lipid antibodies with breadth of protection the in vitro PBMC assay for R5 transmitted/founder strains (Nature Medicine, submitted 2009)”
- - - - - - -
“This publication is currently in press.”
Center for HIV/AIDS Vaccine Immunology
Duke Human Vaccine Institute, DUMC
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45120911

1-13-10, CEO Steve King, OneMedForum/SanFran
UPCOMING MILESTONES FOR 1H 2010:
• Interim data from 2 of our Ph.2 cancer studies (targeting AACR & ASCO for mult. presentations)
• Initiate 3-5 new clinical trials by Q3 2010
• Complete enrollment in the Cotara Ph.2 study (India/exp. to U.S.), with interim update
A number of research pubs. always in the works (“we don’t know exactly when those will pop up, but some are getting close we believe”)
• Expand Commercial Mfg. Opportunities, Gov’t Business
• Initiate a BioSimilars Dev. Plan (where we see a great opportunity moving fwd)
http://tinyurl.com/yb7v2u4